Psychedelic Industry News

The Money Behind the MDMA Resubmission Came From a SpaceX Director

The WSJ reported that a SpaceX director gave $25 million to recapitalize the company behind MDMA-assisted therapy. That explains a strategy that looked strange.

The American Legion Just Backed a Specific Psychedelics Bill, Not Just the Idea

The American Legion adopted a resolution backing psychedelic therapy for veterans. It endorses S.4220, which would build a VA office and ban step therapy.

FDA Called Two Sentences on a Ketamine Booth Extremely Concerning

FDA cited Alar Pharmaceuticals over claims for an investigational ketamine product. The flagged phrases show up in a lot of clinic marketing.

A High THC Dose Felt Like Psilocybin. The Study Had Four People

A Johns Hopkins pilot reported 25 mg of THC produced a psilocybin-like experience. It enrolled four participants and was funded by a cannabis foundation.

New Mexico Just Opened Its First Psilocybin Permits. The One Clinicians Need Is Still Coming

New Mexico began accepting psilocybin producer applications on August 17. The clinician permit has not opened, and the end of 2026 target looks unlikely.

Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster

Lilly paid up to $3.8 billion for a compound whose selling point is a two hour clinic visit. Session length, not efficacy, is now the axis that separates psychedelic programs.

The VA Just Started a Phase 3 Psilocybin Trial. The Control Group Gets Psilocybin Too

The VA began enrolling 240 veterans in a phase 3 psilocybin trial on August 3. There is no placebo arm, and that changes what the study can prove.

MAPS-Funded MDMA Therapy for PTSD Is Back at the FDA, Without a New Phase 3 Trial

MDMA assisted therapy for PTSD appears to be back in front of the FDA. Psychedelic Alpha reported on August 9 that Resilient Pharmaceuticals has resubmitted the application the agency declined two years ago. MAPS responded to that report the next day without independently confirming it. The detail that matters is not the resubmission. It is […]

Eli Lilly Buys 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 Billion, the Largest Psychedelic Deal Yet

Eli Lilly, the world’s largest pharmaceutical company, confirmed Thursday morning that it will acquire AtaiBeckley in a deal worth up to $3.8 billion. The purchase hands Lilly the company’s lead candidate, an intranasal form of 5-MeO-DMT for treatment resistant depression that is now entering Phase 3 trials. No acquisition in psychedelic medicine has come close […]

FDA Finalizes Psychedelic Trial Guidance, Then Opens A Bigger Federal Conversation

The FDA finalized its first formal guidance for studying psychedelic drugs. The document sets the ground rules for research into psilocybin, LSD, and MDMA.